Within the literature on medically treated prolactinomas, the studies of Delgrange et al. [24], Khare et al. [46], and Nishioka et al. [66] all reported a significantly higher level of pre-treatment prolactin in male than female patients and with that a strongly correlating tumor size. This evidence concerns the gene PRL and neoplasm.